Dr. Anthony Berdis is an associate professor in the Department of Chemistry and a member of the Center for Gene Regulation in Health and Disease (GRHD). In addition, he is the Co-Founder and Chief Scientific Officer for Red5 Pharmaceuticals, LLC, an emerging pharmaceutical company developing novel anti-cancer agents targeting drug-resistant cancers. Dr. Berdis is an internationally recognized expert in the synthesis and biological testing of novel therapeutic and diagnostic agents.
Dr. Berdis’s research focuses on developing better treatments for brain cancer, the deadliest of all cancers. His group’s development of an improvement to an FDA-approved drug used to treat brain cancer was featured on News 5 Cleveland in January, and his team is currently performing in-depth safety studies on this compound in order to pursue a Phase I clinical trial within the next two years. He has published more than 80 research papers and book chapters, and his research has been funded by the National Institutes of Health, the National Science Foundation, and the Department of Defense.